| Literature DB >> 12744722 |
H Christof Muller-Busch1, Inge Andres, Thomas Jehser.
Abstract
BACKGROUND: The administration of sedatives in terminally ill patients becomes an increasingly feasible medical option in end-of-life care. However, sedation for intractable distress has raised considerable medical and ethical concerns. In our study we provide a critical analysis of seven years experience with the application of sedation in the final phase of life in our palliative care unit.Entities:
Year: 2003 PMID: 12744722 PMCID: PMC165435 DOI: 10.1186/1472-684X-2-2
Source DB: PubMed Journal: BMC Palliat Care ISSN: 1472-684X Impact factor: 3.234
Guidelines for the use of sedation in patients near death in PCU Havelhoehe
| Otherwise refractory and burdensome symptoms In terminal or final stages of the life of patients with Incurable disease – If death can be expected within the next 48 hrs |
| Informed consent of patient, surrogates and palliative care team |
| Continuous or Intermittent innfusion of sedatives (iv or sc e.g. midazolam 0,5 -mg/h +/- analgesics + co-medlcatlon). Lowest possible, adequate dosage to control symptoms under permanent observation and careful monitoring. Reduction of dosage In agony. Maintenance of all necessary medical and nursing support. Documentation. |
| Reduction of distress, good sleep at night, adequate communication at daytime. Comfort and tolerance In the final phase – not to hasten death. |
Patients characteristics on admission – demographic and clinical data of all patients in comparison to those who died in PCU Havelhoehe 1995–2002. Significant differences were found between groups on age and stages on admission except preterminal stage.
| All admissions (A) | Subgroup (B) | Subgroup (C) | Significance p-values | |
| All patients (n = 1467) | † without sed. (n = 468) | † with sed. (n = 80) | ||
| female | 55.8 | 57.1 | 61.2 | n.s. |
| Mean (SD) | 60,8 (17.8) | 63.6 (13.3)* | 54.3 (14.4)** | *p = 0.026 |
| Range | (19.7–97.7) | (24.6–97.7) | (19.7–81.1) | **P < 0.001. |
| Rehabilitative | 33.3 | 15.1** | 13.8** | **P < 0.001 |
| Preterminal | 44.3 | 42.2 | 43.8 | P = 0.445 |
| Terminal | 19.6 | 36.6** | 38.7** | **P < 0.001 |
| Final | 2.8 | 6.2* | 3.8* | *P = 0.002 |
| Mean (SD) | 21.0 (21.5) | 21.1 (23.6) | 21.5 (20.3) | n.s. |
| Median | 16 | 14.0 | 15.5 | |
| Range | (0 – 233) | (0 – 199) | (1 – 109) | |
| Gastrointestinal | 21.6 | 24.4 | 27.2 | n.s. |
| Breast | 15.4 | 15.6 | 6.2 | P = 0.06 n.s. |
| Lung, bronchus & trachea | 12.8 | 14.9 | 16.0 | n.s. |
| Prostate | 8.8 | 5.2 | 3.7 | n.s |
| Female genital | 8.6 | 9.7 | 14.8 | n.s. |
| Bones, skin & soft tissue | 6.3 | 6.7 | 7.4 | n.s. |
| Nervous system | 3.8 | 3.7 | 1.2 | n.s. |
| Urinary system | 3.8 | 3.7 | 7.4 | P = 0.085 n.s. |
| Oropharynx & hypopharynx | 3.7 | 4.1 | 7.4 | P = 0.085 n.s. |
| Lymphoma | 3.5 | 4.3 | 3.7 | n.s. |
| Others | 1.2 | 2.1 | 4.9 | n.s. |
| 10.5 | 5.6** | 0.0 | P = 0.001 |
Predominant and concomitant symptoms on admission to PCU Havelhoehe.
| All (n = 1467) | † without sed.(n = 468) | † with sed. (n = 80) | p-Values | ||||
| Predominant | Concomitant | Predominant | Concomitant | Predominant | Concomitant | ||
| Pain | 29,1% | 56,3% | 27,1% | 54,0% | 37,5% | 70,0% | n.s. |
| Gastrointestinal (nausea, vomiting, constipation & bowel obstruction) | 17,4% | 71,3% | 11,7%* | 55,9% | 8,8%* | 67,5% | *p = 0.014 |
| Dyspnoea | 14,6% | 31,2% | 15,5% | 33,1% | 22,5% | 46,3% | n.s. |
| Psychological distress (anxiety/depression) | 2,4% | 34,0% | 1,7% | 20,9% | 5,0% | 37,5% | n.s. |
| Cachexia/fatigue | 9,3% | 56,3% | 17,4%** | 65,9% | 12,5% | 66,3% | **p < 0.001 |
| Cognitive disorder/delirium (drowsiness/agitation) | 8,5% | 29,1% | 11,2% | 29,1% | 3,8% | 13,7% | n.s. |
| Bleeding | 2,4% | 3,2% | 1,3% | 3,8% | 0,0% | 1,3% | n.s. |
| Skin (ulceration, oedema) | 5,3% | 42,5% | 3,2% | 31,4% | 2,5% | 35,0% | n.s. |
| Neurological | 8,9% | 33,6% | 8,7% | 27,1% | 6,3% | 26,3% | n.s. |
| Others | 2,1% | 34,2% | 2,2% | 22,0% | 1,1% | 14,5% | n.s. |
Figure 1Percentage of patients with sedation in the last 48 hrs in relation to the number of annual deaths (bars) in care of PCU Havelhoehe between 1995 and 2002. Significant increase of incidence for sedation in the period 2000–2002 (p = 0.015 in paired t-test)
Figure 2Course of pain, dyspnoea, cognitive disorder (delirium) and psychological distress (anxiety) in patients with regard to application of sedation in the final phase (A= Subgroup without sedation, B= Subgroup with sedation). Significance level p < 0.05 in Wilcoxon rank sum test.
Indication for sedation, patients' request and observational reports on communication and oral fluid/nutrition intake comparing the periods 1995–1999 and 2000–2002 (*p < 0.05).
| 80 (14.6) | 31 (10.6) | 49 (18.9)* | **P = 0.007 | |
| Dyspnoea | 28 (35.0) | 11 (35.5) | 17 (34.7) | n.s. |
| Gastrointestinal | 6 (7.5) | 3 (9.7) | 3 (6.1) | n.s. |
| Bleeding | 1 (1.3) | 1 (3.2) | 0 (0.0) | n.s. |
| Pain | 2 (2.5) | 1 (3.2) | 1 (2.0) | n.s. |
| Delirium, agitation | 11 (13.8) | 6 (19.4) | 5 (10.2) | n.s. |
| Anxiety, psychological distress | 32 (40.0) | 9 (29.0) | 23 (46.9) | P = 0.111 |
| 23 (28.8) | 6 (19.4) | 17 (34.4) | P = 0.141 | |
| Mean (SD) | 62.8 (58.0) | 69.0 (57.5) | 58.9 (58.7) | P = 0.445 |
| Range | 2–264 | 15 – 240 | 2 – 264 | |
| Mainly somatic indication | 63.3 (56.3) | 84.7 (64.0) | 47.3 (45.1) | P = 0.117 |
| Mainly psychological indication | 62.6 (60.3) | 52.2 (46.0) | 68.3 (67.1) | P = 0.145 |
| Patients with request for sedation | 57.3 (47.3) | 73.0 (53.0) | 51.8 (45.2) | P = 0.198 |
| Continuous, | 48 (60.0) | 15 (48.4) | 33 (67.3) | P = 0.092 |
| Intermittent, | 32 (40.0) | 16 (51.6) | 16 (32.7) | P = 0.092 |
| With communication, | 42 (51.3) | 16 (51.5) | 26 (53.1) | n.s. |
| With oral fluid intake, | 53 (66.3) | 15 (48.4) | 38 (77.6)* | P = 0.007 |
| With oral nutrition, | 10 (12.5) | 5 (16.1) | 5 (10.2) | n.s. |